IPA's Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments

Author's Avatar
Dec 08, 2022

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that its subsidiary, BioStrand BV, has completed the full integration of 20 million Structural HYFTswith Deepmind’s AlphaFold and META’s ESM-2 Fold platforms.